<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148551</url>
  </required_header>
  <id_info>
    <org_study_id>01 (C03 - 0236)</org_study_id>
    <nct_id>NCT00148551</nct_id>
  </id_info>
  <brief_title>Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.</brief_title>
  <official_title>Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Retinal Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Retinal Trials Group</source>
  <brief_summary>
    <textblock>
      A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT
      therapy in conjunction with intravitreal triamcinolone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the effect of Triamcinolone Acetonide in conjunction with
      photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes
      secondary to age-related macular degeneration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in visual acuity from baseline.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lesion characteristics from baseline.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with predominantly classic, subfoveal CNV secondary to AMD.

          -  No previous PDT Treatment in study eye.

        Exclusion Criteria:

          -  CNV from conditions, other than AMD.

          -  Other disease that could be responsible for decreased vision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Maberley, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>July 26, 2007</last_update_submitted>
  <last_update_submitted_qc>July 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2007</last_update_posted>
  <keyword>AMD</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>Macular Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

